1. Introduction {#sec0001}
===============

Schizophrenia and obsessive-compulsive disorder (OCD) are frequently comorbid ([@bib0020]). Several studies have shown that schizophrenia patients treated with second generation antipsychotics will develop symptoms of obsessive-compulsive disorder (OCD) ([@bib0026]) with the proportion being around half ([@bib0009]). To date, no replicated clinical risk factors have been found that help to identify vulnerable cases prior to treatment initiation. The clinical impact of this comorbidity on the patients' social functioning and quality of life is largely unknown.

Indeed, studies investigating patient outcome and level of functioning in antipsychotic induced OCD are sparse and need further clarification ([@bib0008], [@bib0014], [@bib0017], [@bib0021], [@bib0030], [@bib0033]). Studies have shown lower scores in self rated and foreign rated measures of wellbeing in those cases with antipsychotic-induced OCD compared to those without, with higher depressive symptoms, suicidality, hospitalisation, poorer physical and psychological health ([@bib0008], [@bib0017], [@bib0030], [@bib0033]). In addition, interpersonal relationship scores were lower in those with OCD ([@bib0033]) and OCD cases may also show more motor symptoms ([@bib0021]). Alternatively, one study showed no significant difference in outcome measures ([@bib0014]) when using foreign rated measures such as the Quality of Life Scale. Some studies which have investigated cognitive outcomes eg with an fMRI approach and in longitudinal studies ([@bib0027], [@bib0029]) found specific and longitudinally stable cognitive impairments associated with OCD comorbid schizophrenia.

Therefore, further studies of larger and well characterised samples are needed.

There are no reliable clinical risk factors identified for developing OCD that can help the clinician to predict who will be at greater risk. Indeed, even the exact mechanism and prevalence of antipsychotic-induced OCD remain unclear. Those antipsychotics with greater anti-serotoninergic action, such as clozapine and olanzapine, have been more often associated with OCD onset ([@bib0022], [@bib0025]). The prevalence ranges from less than 5% ([@bib0018]) to 74% ([@bib0025]), reflecting not only different methodologies used but also the differences in the clinical samples included. However, only a few of these studies ([@bib0013], [@bib0023]) were investigating OCD risk factors specifically in cohorts of schizophrenia patients, and they had limited sample size. [@bib0013] found greater severity of depression and family history of OCD in the cohort with comorbid OCD. [@bib0023] also found that relatives of OCD-schizophrenia patients had higher morbid risk. Recent study also pointed to the possibility of co-prevalence of motor disorders prior to OCD development in psychotic disorders ([@bib0010], [@bib0032]). Nevertheless, these findings need further replication in larger samples.

It is likely that antipsychotic-induced OCD and 'pure' OCD might share risk factors such as genetic, neurodevelopmental, immune and perinatal triggers. Demographic risk factors for 'pure' OCD include advanced maternal ([@bib0005], [@bib0031]) and paternal age ([@bib0035]), perinatal events such as preterm birth, prolonged birth, low birth weight, breech, caesarean and forceps deliveries ([@bib0002], [@bib0024]). Cross sectional population studies suggested that gender modulated the risk of OCD onset according to age with the highest risk in adolescent males ([@bib0031]) and adult females ([@bib0007], [@bib0012]). Later in life, social factors such as social isolation, previous physical abuse ([@bib0015]), maternal overprotection ([@bib0034]) and drugs, especially cocaine and cannabis ([@bib0007]) misuse were recognised as risk factors for 'pure' OCD. There is a substantial body of work exploring genetic risk factors. Multiple candidate genes have been found for 'pure' OCD ([@bib0019]) and associations with candidates such as the SLC1A1 gene has been found in both primary and antipsychotic associated OCD. This has however been difficult to replicate in follow up studies across ethnicities ([@bib0028]). In addition, genes have been found which share polygenic risk with both OCD and schizophrenia ([@bib0006])

One potential explanation of the lack of clinical risk factors for developing OCD in antipsychotic-treated patients could be the mis-identification of cases. In a recent report by [@bib0009] using a large cohort of clozapine treated patients, we identified a few factors that might have acted as confounders in prior studies. For instance, we found rising OCD prevalence and checking compulsion to be associated with increasing years of treatment. Development of OCD in this cohort could be a combination of underlying vulnerability and anti-psychotic treatment, so it is possible that a patient without OCD after 5 years of treatment might still be mis-identified as non-case despite going on to develop OCD later. We also found that psychosis severity correlated with OCD and obsessions severity which could potentially over-represent OCD cases in those more floridly psychotic. Such distinctions have barely been considered in prior studies of the sociodemographic and clinical risk factors of antipsychotic-induced OCD.

Our aims for this study were to a) determine if comorbid OCD is associated with a poorer outcome measures such as global functioning and subjective wellbeing, and b) identify the clinical and sociodemographic factors associated with antipsychotic-induced OCD. We used the electronic records of a large cohort of clozapine treated patients who were carefully clinically phenotyped, including using standardised scales for OCD. In order to maximise the group differences, decided on a strategy of selecting the two ends of the clinical phenotype (with and without OCD) of clozapine-treated patients as this drug is more strongly associated with OCD-onset. We then performed a whole sample analysis as a confirmatory step.

2. Experimental procedures {#sec0002}
==========================

It is of note that we covered the prevalence and complex phenomenology of obsessions and compulsions in clozapine-treated patients in a previous work ([@bib0009]). Here, we use the term OCD to define these phenomena, albeit acknowledging the open debate about its pathophysiology and correct terminology.

2.1. Study design {#sec0003}
-----------------

This is a cross sectional, single centre study of a cohort of clozapine treated patients at the Cambridgeshire and Peterborough NHS Foundation Trust. The study included anonymised electronic clinical records of all cases from August 2015 to April 2018, embedded in an ethically approved database for research and clinical purposes (13/EE/0121). All cases were reviewed by the same care consultant (EFE).

2.2. Participants {#sec0004}
-----------------

The clinical records of all schizophrenia patients treated with clozapine were initially included in this study.

2.3. Assessment {#sec0005}
---------------

Routine clinical assessments are described elsewhere ([@bib0009]) and include full psychiatric history, comprehensive mental state examination, current medication list, smoking habit, legal and illegal drug history, early life history, clozapine treatment length and side effects assessment and physical health assessment. Among others, psychopathological scales included assessment for general functioning \[Global Assessment of Functioning (GAF)\]([@bib0016]), short version of the Warwick-Edinburgh Wellbeing Scale \[SWEWBS\]([@bib0003]) and symptom severity using the Clinical Global Impression (CGI) for Schizophrenia ([@bib0004]) which includes 5 domains (positive, negative, cognitive, and depressive) rating from 1 to 7 for absence to extreme severity.

The Obsessive-Compulsive Inventory Revised version (OCI-R) was the questionnaire used for determining cut off scores for OCD diagnosis ([@bib0011]). This widely used 18 item self-rated questionnaire is done annually in these patients. Each question has a five-point Likert-type score measuring the degree of distress experienced with common OCD phenomena (not at all to extremely). It also contains six sub-scales measuring severity for obsessions, checking, washing, hoarding, neutralising and ordering. A cut-off of 21 for the total scale or above 5 for subscales is considered for OCD diagnosis ([@bib0011]). In a previous study, we showed that OCI-R and its six-factor component had a valid goodness-of-fit and structure in clozapine-treated patients ([@bib0009]).

2.4. Inclusion and exclusion criteria {#sec0006}
-------------------------------------

The exclusion criteria were: 1) cases with no primary psychotic disorder (off label use of clozapine), 2) those cases in which documented OCD predated clozapine use and 3) and cases that neither showed clear OCD symptoms nor had a clear absence of OCD symptoms. The latter criterion was set to maximise the group differences and reduce false positives and we selected the two ends of the clinical phenotype (with and without OCD). We considered the duration of treatment, severity of the obsessive-compulsive symptoms and the checking symptoms severity, as they are the most commonly reported symptoms. Length of clozapine treatment was relevant as some might have not yet expressed the vulnerability. In this study, OCD was considered if an OCI-total score  ≥ 24 or checking subscale  ≥ 6 regardless of treatment duration. Whereas an OCI-total score \<15, checking subscale \<4, no treatment for OCD, and a treatment duration longer than 5 years for the non-OCD group were considered. To note, we used a more strict score criteria for OCD, of 24 instead of 21, in order to include cases with uncontroversial OCD diagnosis.

2.5. Statistical analysis {#sec0007}
-------------------------

All statistical analyses were conducted using SPSS v23.0, with a two-tail 0.05 significance level and R studio Version 1.0.136. Data are presented as mean (*M*) and standard deviation (SD). Two independent data analyses were performed as follows: the impact of developing antipsychotic-induced OCD was assessed comparing global functioning and subjective wellbeing using a series of Multivariate ANOVAs (MANOVA). To identify the risk factors for developing OCD, we used the following list of potential risk factors for both antipsychotic-induced OCD and general OCD literature: paternal and maternal age, birth weight, hand dominance, family history of psychosis and OCD, age at presentation of schizophrenia, gender, treatment dose and duration, smoking habit, comorbidities with other psychiatric disorders and whether or not the psychosis was initially triggered by drug use. For this part of the analysis, we used 2-tailed Students t-tests for normally distributed continuous data, Mann--Whitney *U* test for not normally distributed continuous data and χ^2^ test for categorical variables and a MANOVA according to the analysis needs. A confirmatory analysis was conducted with the whole sample using a Multivariate Linear regression.

3. Results {#sec0008}
==========

The database contained two hundred thirty-one patients on clozapine with primary diagnosis of non-affective psychosis. Of those, seventy-four were missing the OCI-R scores and were not included in the analysis. Eight patients were excluded due to prior OCD diagnosis. One patient was excluded due to confirmed learning disability.

Sixty-three patients were excluded for having an OCI-R total score between 15 and 24 and/or a checking subscale score between 4 and 6. The final sample of 85 participants consists of 29 schizophrenia patients without OCD symptoms (4 females, 25 males; mean age = 45.24, SD = 12.66, range: 27--70 years) and 56 patients with OCD symptoms (14 females, 42 males; mean age 48.29 SD = 9.76, range: 29--69 years). Eleven out of 56 patients in the OCD group and 6 out of 29 patients in the non-OCD group were missing their parent\'s age at birth. Two participants in the non-OCD group were missing the hand dominance data. 11 patients in the non-OCD group and 24 in the OCD group did not know their birth weights. 17 participants without OCD and 31 with OCD symptoms could not provide their family history. [Table 1](#tbl0001){ref-type="table"} shows the descriptive statistics and the significance values for differences between OCD and non-OCD groups for all variables.Table 1Description of the risk factors.Table 1OCDNon-OCD*pN*5629Age at presentation (*M* ± SD)21.36 ± 4.921.34 ± 5.90.518Gender male (%)7586.20.275Father\'s age at birth (*M* ± SD)29.6 ± 6.1133.52 ± 80.028\*Mother\'s age at birth (*M* ± SD)27.02 ± 5.0630.17 ± 6.330.056Treatment dose (*M* ± SD)349.55 ± 123.35264.66 ± 1440.006^⁎⁎^Treatment duration (*M* ± SD)16 ± 7.716.14 ± 6.240.951Low birth weight (%)8.9[a](#tb1fn1){ref-type="table-fn"}6.9[a](#tb1fn1){ref-type="table-fn"}0.786Current smoking (%)32.1310.56Comorbidities (%)0.667 Depression/schizoaffective disorder10.76.9 Anxiety/panic/phobia5.410.3 PTSD03.4 Drug/alcohol misuse5.410.3Family history (%)0.728 Psychosis/bipolar disorder in 1st degree relatives12.524.1 OCD/affective disorders in 1st degree relatives14.310.3 Psychosis/bipolar disorder in 2nd degree relatives10.76.9Hand dominance (%)0.261 Right76.869 Left17.920.7 Both5.43.4[b](#tb1fn2){ref-type="table-fn"}Psychosis triggered by drug use (%)46.448.30.733 Type of presentation (%)0.052 Hallucination/delusion94.679.3 Psychosis part of mania/affective disorder1.810.3 Non-positive presentation06.9 Unknown3.63.4[^2][^3][^4]

3.1. Impact of antipsychotic-induced OCD in patient rated wellbeing and functioning {#sec0009}
-----------------------------------------------------------------------------------

A series of MANOVA were conducted to assess the impact of OCD versus no-OCD (independent variable) on the GAF, CGI-Positive, CGI-Negative, CGI-Depressive, CGI-Cognitive, CGI-Overall, and the Wellbeing scores.

The results ([Fig. 1](#fig0001){ref-type="fig"}) show a significant effect of group on wellbeing scores, *F*(1, 83) = 22.017, *p* \< 0.001. Patients with OCD symptoms had a lower wellbeing score (*M* = 21.95, SD = 4.33) compared with the non-OCD group (*M* = 27.10, SD = 5.60). The presence of OCD also had a significant effect on the CGI-Positive scores, *F*(1) = 18.48, *p* \< 0.01). There were higher scores in the OCD-schizophrenia group (*M* = 3.0, SD = 1.44) compared with the schizophrenia group without OCD (*M* = 2.0, SD = 1.47). In addition, the MANOVA results showed that belonging to OCD versus non-OCD group also influenced the CGI-Depressive scores significantly, *F*(1) = 4.046, *p* \< 0.05, with higher depressive scores in schizophrenia-OCD group (*M* = 2.8, SD = 1.16) compared with the other group without OCD (*M* = 2.97, SD = 1.57). There was no effect of group on the GAF and the CGI-Negative scores. [Table 1](#tbl0001){ref-type="table"} shows the MANOVA results for all variables.Fig. 1(A) Shows the average scores on different subsets of the Clinical Global Impression (CGI) scale. (B) Shows the average scores on the Global Assessment of Functioning (GAF) rated by clinicians and the Wellbeing scores rated by patients themselves. The Wellbeing scores are converted to percentages. The significance levels of *p* \< 0.05, *p* \< 0.01, and *p* \< 0.001 are indicated with one, two and three stars respectively.Fig. 1

3.2. Risk factors for developing OCD {#sec0010}
------------------------------------

Next, we were interested to understand the clinical and sociodemographic factors associated with antipsychotic-induced OCD. A 2-tailed Students *t*-test was used to examine the impact of parents' age, treatment dose and duration on the OCD symptoms development since these variables were continuous and normally distributed.

There were significant differences between groups for the father\'s age at birth and the treatment dose. Significantly more patients with OCD symptoms had a younger father at birth (*M* = 29.60, SD = 6.11) and a higher treatment dose (*M* = 349.5,SD = 123.35) compared to those without OCD symptoms who had an older father (*M* = 33.52, SD = 8) and were on a lower dose (*M* = 264.66, SD = 144), the *t*-test results are respectively *t*(66) = 2.25, *p* = 0.028 and *t*(83) = 2.84, *p* \< 0.01. However, there was no significant difference between groups for the number of years they have been treated with clozapine *t*(83) = −0.062, *p* = ns.

A Mann--Whitney *U* test was performed to assess the associations between belonging to each group and the mother\'s age at birth and the patient\'s age at first presentation of psychosis since these variables were continuous and not normally distributed. The mother\'s age at birth was lower in the OCD group (*M* = 27.02; SD = 5.06) compared with the non-OCD schizophrenia group (*M* = 30.17; SD = 6.33). However, this difference did not reach significance, *U* = 370.5, *p* = 0.056. There was no significant difference for the age at presentation between the two groups *U* = 742, *p* = ns.

The χ^2^ test was performed to assess the differences between groups with gender, comorbidities with other psychiatric disorders, impact of a lower birth weight, family history of psychosis and OCD, hand dominance, current smoking and whether the psychosis was triggered by drug use, as these variables were categorical in nature. None of these associations reached significance (see [Table 1](#tbl0001){ref-type="table"}).

A multiple linear regression was calculated as a second confirmatory analysis using the whole sample of patients with OCI total scores as dependant variable and all the risk factor variables described above. The best model with the highest adjusted-*R*^2^ was the one with years on clozapine, gender, father\'s age at birth, family history of psychosis and OCD, treatment dose of clozapine and smoking habit as independent variables. A significant regression equation was found (*F*(12,110) = 1.885, *p* \< 0.5), with an adjusted-*R*^2^ of 0.08. Only treatment dose was a significant predictor of the OCI total score (*t* (110) = 2.949, *p* \< 0.001). The family history of psychosis together with a first degree relative OCD diagnosis seem to also be associated with higher scores of the OCI total, however, it did not reach significance level (*t* (110) = 1.853, *p* = 0.06).

4. Discussion {#sec0011}
=============

In this study, we found that schizophrenia patients with clozapine-induced OCD had a lower subjective wellbeing score but not a diminished clinician-rated level of functioning. In our sample, younger paternal age and higher clozapine dose were significant risk factors for developing OCD. Thus, we identified fewer risk factors for OCD onset compared to previous studies, which could be due to our very selective patient selection process. It is of note that we set restrictive inclusion criteria that considered OCI-R total score, checking subset, and length of treatment. This strategy was adopted to minimise the mis-identification of cases. Indeed, sixty-three patients (more than a quarter of all the cases) were excluded due to having mid-range OCI-scores, who might have not developed clinical OCD due to short exposure to clozapine.

The multiple linear regression analysis in the whole sample differed in some respects. It still confirmed that role of treatment dose seems to have a significant impact on the OCI total scores. Nevertheless, we need to be cautious with this analysis, as when using the whole sample the risk of mis-identification of cases was high. For example, a mid-range OCI score could actually be a case due to not yet being on clozapine long enough to manifest, or a non-case due to a falsely high total OCI-R score from florid psychotic symptoms. In addition, there are likely multiple other factors involved in the development of OCD in schizophrenia, not least of which are genetic factors ([@bib0028]) which have not been explored in this paper.

Patients with schizophrenia who develop OCD showed worse functioning as measured by significantly lower wellbeing scores (as subjectively scored by the patients themselves). This is in concordance with previous work ([@bib0008], [@bib0030], [@bib0033]), which used self rated scales to assess quality of life. In our study, a clinician-scored GAF scale was also used. Notably, there was no significant difference between groups. The previous study not finding any association between OCS and outcome measures also used clinician rated quality of life measure ([@bib0014]). However, the clinician rated CGI scale showed increased depressive scores in the OCD cohort, which could be an indicator of the impact of the additional diagnosis on patient wellbeing or potentially due to the greater degree of positive symptoms as they also had higher CGI-positive scores. There is an indication that clinicians can be unaware of the degree to which having OCD can negatively impact the patients' lives. The lack of awareness can therefore lead to patients not receiving adequate treatment for their OCD symptoms. The reasons for a lack of insight could be inadequate screening, of both patient\'s OCD symptoms and also their personal concerns. Increasing the awareness of the comorbidity as well as the routine use of screening tools might be of help to identify and treat these patients.

In the OCD group, we found higher CGI-positive scores, implying greater degree of positive symptoms of schizophrenia in the OCD cohort compared to non-OCD group. This could be consistent with a cognitive theory of the development of OCD in anti-psychotic induced schizophrenia ([@bib0009]). We have previously found that checking was the most prevalent symptom that developed after clozapine treatment. Pending of further replication, it was proposed that there may be two OCD stages in clozapine-treated psychosis. The initial goal directed checking behaviour in OCD was triggered by positive symptoms of psychosis i.e. checking due to delusional hypervigilance. Once the obsessional positive symptoms are improved, and perhaps due to the potent clozapine-induced anti-serotoninergic action, the residual checking phenomenon became part of the habit, developing a full OCD. Therefore, whether a patient has positive symptoms initially, could affect how likely they are to develop ongoing checking behaviour. Those exhibiting mainly positive schizophrenia symptoms at the beginning being more likely to have it incorporated into the checking behaviour of OCD. There was a trend for type of initial presentation, with greater proportion of schizophrenia-OCD cohort having presented with positive symptoms; however, the association did not attain statistical significance.

Younger paternal age was the only significant socio-demographic factor associated with the onset of OCD symptoms in patients with schizophrenia, which is a novel finding. It is in contrast with the only existing study that showed an increased OCD risk with increasing paternal age ([@bib0035]). However, this study did not study OCD development in existing schizophrenia.

The higher treatment doses of clozapine in the OCD group replicates previous findings ([@bib0001], [@bib0009]) and remained consistent in confirmatory multilinear regression analysis. This could have various explanations such as biological sex, where males require higher doses, and smoking status, where smokers require higher doses. However, there were no significant differences in sex or smoking status (current or historical) between groups. Previous studies have shown an association between OCD severity and clozapine dose ([@bib0021], [@bib0025]). When comparisons are made between the more representative plasma clozapine levels and OCD symptoms, which would remove the issues of compliance and different pharmacokinetics, the association no longer remains significant ([@bib0009], [@bib0025]). The severity of positive symptoms could be a confounding factor in the relationship between clozapine dose and OCD severity, due to more severe symptoms of schizophrenia in the OCD group leading to increased requirement of clozapine.

4.1. Limitations {#sec0012}
----------------

There were strengths in this study, such as the comparatively larger number of subjects available, and the use of many well validated scoring scales. However as this is a cross sectional study, we are unable to take a longitudinal view to explore causality. We were also unable to carry out genetic studies or neuro-imaging, due to the origin of the data being from the routine clinic work. These points can however be used in preparation for future studies e.g. into genetic associations which has been planned as a follow up study to explore causality. Assessing family history in our sample was also difficult, due to the information source being the patients themselves. Patients were presenting to clinic with symptoms of psychosis, so their recollections may not have been an accurate representation. This could explain why our findings did not replicate some of the previous results ([@bib0013], [@bib0023]).

4.2. Conclusion {#sec0013}
---------------

In conclusion, an additional comorbidity of OCD significantly lowers the wellbeing of schizophrenia patients on subjective scales, especially those with higher positive and higher depressive symptoms. It is clear that there is also an incongruence between physician reported and patient reported quality of life results. Further research could be warranted, with increased clinician screening for OCD in reviews, and using both types of tools in screening as a goal in the clinical setting. With regards to risk factors, there were very few specific markers, either clinical or socio-demographic which could account for the development of OCD in schizophrenia. Although paternal age and clozapine dose were significant, their effects did not account for enough of the difference between groups. The possibility of a positive family history being associated with OCD development shows there is scope for future studies based on imaging and genetic studies to further closely investigate causality.
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